|drug4054||retrospective metagenomics on clinical samples collected during hospitalization Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
Up to 2000 Marshallese will complete an online or telephone survey. Among those who complete the survey, 40 participants will be randomly selected and invited to complete an in-depth qualitative interview. This survey will collect data describing the impact of COVID-19 on self-reported Marshallese persons in the United States. Data collected will help describe: 1) risk exposure, 2) knowledge of preventive recommendations, 3) barriers and facilitators to implementing preventative recommendations, 4) barriers and facilitators to COVID-19 testing when appropriate, and self-care behaviors during COVID-19.
Description: Respondents will be asked how COVID-19 has impacted mulitple facets of their lives, including housing, food security, and employment and incomeMeasure: Effects of COVID-19 on social determinants of health Time: Baseline
Description: Respondents will be asked to rate their general health and mental health now and compared with before the COVID-19 outbreakMeasure: Effects of COVID-19 on general health status and mental health Time: Baseline
Description: Respondents with type 2 diabetes will be asked to compare their current self-care behaviors with before the COVID-19 outbreak using multiple items, including the Summary of Diabetes Self-Care Activities (adapted to include retrospective pre-COVID-19 comparisons of behaviors)Measure: Effects of COVID-19 on disease management Time: Baseline
Description: Using Behavioral Risk Factor Surveillance System items and relevant items from the Summary of Diabetes Self-Care Activities, respondents will be asked to compare their current diet and physical activity behaviors with before the COVID-19 outbreakMeasure: Effects of COVID-19 on diet and physical activity behaviors Time: Baseline
Description: Respondents will be asked to report whether they have been screened for COVID-19 (and how), whether they have been tested for COVID-19 (and how), whether they would accept a COVID-19 vaccine, and what specific actions they have taken to prevent being infected by COVID-19Measure: COVID-19 screening, testing, and prevention Time: Baseline
Description: Respondents will be asked to report which sources of information they use the most and trust the most to stay informed about COVID-19Measure: Trusted sources of COVID-19 information Time: Baseline
Description: Respondents will be asked to report how the COVID-19 outbreak has impacted their daily lives, including health concerns, impacts on family, and access to healthcareMeasure: Impacts of COVID-19 on daily life Time: Baseline
Description: Respondents will be asked to report how likely they feel they are to be infected, their chances of dying if infected, how easy it is to avoid being infected, and how concerned they are with what could result from being infected (e.g., losing a job, infecting others, being isolated)Measure: COVID-19 attitudes, fears, and beliefs Time: Baseline
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports